The pioneering pilot study at HCG Cancer Hospital Bengaluru introduces low-dose immunotherapy using Nivolumab to revolutionize head and neck cancer treatment.

In this study, low-dose Nivolumab was combined with the TPF regimen (docetaxel, cisplatin, and 5-fluorouracil) in neoadjuvant therapy, demonstrating remarkable efficacy and cost-effectiveness while avoiding additional side effects. The multicentric, prospective, randomized trial seeks to improve the well-being and survival of patients with locally advanced buccal mucosal carcinoma.

The 12 cases studied (ages 54 to 76) all had significant tumor reduction exceeding 90%, highlighting the affordability and safety of low-dose immunotherapy compared to full-dose treatment.

Dr B S Ajaikumar, Executive Chairman of Healthcare Global Enterprises Limited, said,

“Cancer is fast becoming a chronic disease, and a sea change has occurred in how we stage cancer as we adopt a multi-disciplinary approach to treatment. At HCG, head and neck cancer cases represent a significant portion of the caseload. Despite the comprehensive approach, preventing the recurrence and spread of these cancers remains a significant challenge.

Today, with this announcement, we embark on a journey to revolutionize head and neck cancer treatment. This study has the potential to be a game-changer in the sphere of head and neck cancer treatment. The initiative reflects HCG’s commitment to advancing research and academia in India, positioning the Organisation as a leader in this vital healthcare domain.”